文献速递妇科

子宫平滑肌瘤的表观基因组与增强子失调

Epigenomic and enhancer dysregulation in uterine leiomyomas.
PubMed 文献 · Hum Reprod Update · 2022-01-01

本文综述子宫平滑肌瘤中DNA甲基化异常、组蛋白尾部修饰及组蛋白变体交换等表观基因组改变,及其对靶基因结构和转录的影响;并讨论增强子三维结构变化如何远程调控基因表达,以及这些发现在非手术治疗中的转化意义。

要点

  • 全基因组DNA甲基化分析发现启动子异常甲基化伴随基因表达抑制或过表达。
  • 异常DNA甲基化或组蛋白修饰改变增强子结构,影响增强子-启动子接触强度。
  • 表观基因组改变参与调控肿瘤抑制、凋亡、血管生成、细胞外基质及干细胞分化等基因。

核心结论

  • 表观基因组异常参与子宫平滑肌瘤的表型表现,全面理解其确切发病机制有助于预防和可行的非手术治疗。

研究设计与样本

  • 综述,检索PubMed截至2021年9月的文献,讨论文章多发表于2015年至2021年间,部分2015年前的关键发现作为背景纳入。

主要发现

  • 全基因组DNA甲基化分析揭示 subsets of either suppressed or overexpressed genes accompanied by aberrant promoter methylation。
  • 改变的三维染色质结构和组蛋白修饰导致的差异启动子可及性参与调控与平滑肌瘤病因相关的关键基因转录。
  • 异常DNA甲基化或组蛋白修饰改变增强子结构,导致增强子-启动子接触强度变化,为 mediator complex subunit 12 突变肌瘤中 high mobility group AT-hook 2 过表达和基因失调提供新解释。
  • 失调基因在肿瘤抑制、凋亡、血管生成、细胞外基质形成、多种癌症相关信号通路和干细胞分化中发挥作用。
  • 尽管已研究许多分子机制和表观基因组特征,Black人群中观察到的种族差异基础仍不清楚。

局限性

  • 原文指出尚缺乏对子宫平滑肌瘤确切发病机制的全面理解,需加以关注。
  • 原文指出Black人群中观察到的种族差异基础仍不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uterine leiomyomas, also known as uterine fibroids or myomas, are the most common benign gynecological tumors and are found in women of reproductive and postmenopausal age. There is an exceptionally high prevalence of this tumor in women by the age of 50 years. Black women are particularly affected, with an increased incidence, earlier age of onset, larger and faster growing fibroids and greater severity of symptoms as compared to White women. Although advances in identifying genetic and environmental factors to delineate these fibroids have already been made, only recently has the role of epigenomics in the pathogenesis of this disease been considered. OBJECTIVE AND RATIONALE: Over recent years, studies have identified multiple epigenomic aberrations that may contribute to leiomyoma development and growth. This review will focus on the most recent discoveries in three categories of epigenomic changes found in uterine fibroids, namely aberrant DNA methylation, histone tail modifications and histone variant exchange, and their translation into altered target gene architecture and transcriptional outcome. The findings demonstrating how the altered 3D shape of the enhancer can regulate gene expression from millions of base pairs away will be discussed. Additionally, translational implications of these discoveries and potential roadblocks in leiomyoma treatment will be addressed. SEARCH METHODS: A comprehensive PubMed search was performed to identify published articles containing keywords relevant to the focus of the review, such as: uterine leiomyoma, uterine fibroids, epigenetic alterations, epigenomics, stem cells, chromatin modifications, extracellular matrix [ECM] organization, DNA methylation, enhancer, histone post-translational modifications and dysregulated gene expression. Articles until September 2021 were explored and evaluated to identify relevant updates in the field. Most of the articles focused on in the discussion were published between 2015 and 2021, although some key discoveries made before 2015 were included for background information and foundational purposes. We apologize to the authors whose work was not included because of space restrictions or inadvertent omission. OUTCOMES: Chemical alterations to the DNA structure and of nucleosomal histones, without changing the underlying DNA sequence, have now been implicated in the phenotypic manifestation of uterine leiomyomas. Genome-wide DNA methylation analysis has revealed subsets of either suppressed or overexpressed genes accompanied by aberrant promoter methylation. Furthermore, differential promoter access resulting from altered 3D chromatin structure and histone modifications plays a role in regulating transcription of key genes thought to be involved in leiomyoma etiology. The dysregulated genes function in tumor suppression, apoptosis, angiogenesis, ECM formation, a variety of cancer-related signaling pathways and stem cell differentiation. Aberrant DNA methylation or histone modification is also observed in altering enhancer architecture, which leads to changes in enhancer-promoter contact strength, producing novel explanations for the overexpression of high mobility group AT-hook 2 and gene dysregulation found in mediator complex subunit 12 mutant fibroids. While many molecular mechanisms and epigenomic features have been investigated, the basis for the racial disparity observed among those in the Black population remains unclear. WIDER IMPLICATIONS: A comprehensive understanding of the exact pathogenesis of uterine leiomyoma is lacking and requires attention as it can provide clues for prevention and viable non-surgical treatment. These findings will widen our knowledge of the role epigenomics plays in the mechanisms related to uterine leiomyoma development and highlight novel approaches for the prevention and identification of epigenome targets for long-term non-invasive treatment options of this significantly common disease.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Mlodawska OW, Saini P, Parker JB, et al. Epigenomic and enhancer dysregulation in uterine leiomyomas. Hum Reprod Update. 2022. PMID: 35199155. doi:10.1093/humupd/dmac008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。